148 related articles for article (PubMed ID: 11175341)
1. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
Tari AM; Hung MC; Li K; Lopez-Berestein G
Oncogene; 1999 Feb; 18(6):1325-32. PubMed ID: 10022814
[TBL] [Abstract][Full Text] [Related]
3. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
4. The HER2/Grb2/Akt pathway regulates the DNA binding activity of AP-1 in breast cancer cells.
Mendoza-Gamboa E; Siwak DR; Tari AM
Oncol Rep; 2004 Oct; 12(4):903-8. PubMed ID: 15375520
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
6. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells.
Söderlund K; Pérez-Tenorio G; Stål O
Int J Oncol; 2005 Jan; 26(1):25-32. PubMed ID: 15586221
[TBL] [Abstract][Full Text] [Related]
7. Heregulin regulation of Akt/protein kinase B in breast cancer cells.
Liu W; Li J; Roth RA
Biochem Biophys Res Commun; 1999 Aug; 261(3):897-903. PubMed ID: 10441522
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the Csk homologous kinase facilitates phosphorylation of Akt/PKB in MCF-7 cells.
Zagozdzon R; Bougeret C; Fu Y; Avraham HK
Int J Oncol; 2002 Dec; 21(6):1347-52. PubMed ID: 12429987
[TBL] [Abstract][Full Text] [Related]
9. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
10. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Wellstein A; Morgan E; Czubayko F; List HJ; Reiter R; Martin MB; Stoica A
Oncogene; 2003 Apr; 22(14):2073-87. PubMed ID: 12687010
[TBL] [Abstract][Full Text] [Related]
11. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
Tan M; Li P; Klos KS; Lu J; Lan KH; Nagata Y; Fang D; Jing T; Yu D
Cancer Res; 2005 Mar; 65(5):1858-67. PubMed ID: 15753384
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
13. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.
Janes PW; Daly RJ; deFazio A; Sutherland RL
Oncogene; 1994 Dec; 9(12):3601-8. PubMed ID: 7970720
[TBL] [Abstract][Full Text] [Related]
14. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
15. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
16. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
17. Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway.
del Rincón SV; Rousseau C; Samanta R; Miller WH
Oncogene; 2003 May; 22(22):3353-60. PubMed ID: 12776186
[TBL] [Abstract][Full Text] [Related]
18. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.
Fiddes RJ; Janes PW; Sanderson GM; Sivertsen SP; Sutherland RL; Daly RJ
Cell Growth Differ; 1995 Dec; 6(12):1567-77. PubMed ID: 9019162
[TBL] [Abstract][Full Text] [Related]
19. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
[TBL] [Abstract][Full Text] [Related]
20. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
